Global Influenza Diagnostics 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI01243139

Publication Date:

January 4, 2024

Pages:

100

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Influenza Diagnostics market size was valued at US$ 2284.7 million in 2023. With growing demand in downstream market, the Influenza Diagnostics is forecast to a readjusted size of US$ 3558.7 million by 2030 with a CAGR of 6.5% during review period.
The research report highlights the growth potential of the global Influenza Diagnostics market. Influenza Diagnostics are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Influenza Diagnostics. 麻豆原创 players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Influenza Diagnostics market.
Influenza is an infectious disease and affects the upper respiratory tract in humans. The disease is common in children and elderly population (aged 65 years and above). The disease has a huge impact on Public Company health. Influenza A virus poses a greater risk as compared to the influenza B virus. The B virus is responsible for 20% to 25% of infections globally. Proper collection, storage and transport of respiratory specimens are the essential first step for laboratory detection of influenza virus infections. Laboratory confirmation of influenza virus from throat, nasal and nasopharyngeal secretions or tracheal aspirate or washings is commonly performed using direct antigen detection, virus isolation, or detection of influenza-specific RNA by reverse transcriptase-polymerase chain reaction (RT-PCR).
North America is the largest consumption place, with a consumption marker share nearly 53%. Following North America, Europe is the second largest consumption place with the consumption market share of 25%.
The main manufacturers are BD, Abbott (Include Alere), Roche, SIEMENS, Analytik Jena, Quidel, Thermo Fisher, Meridian Bioscience, BioMerieux, Sekisui Diagnostics, Response Biomedical, SA Scientific etc. BD is the largest manufacturer with about 19% market share.
Key Features:
The report on Influenza Diagnostics market reflects various aspects and provide valuable insights into the industry.
麻豆原创 Size and Growth: The research report provide an overview of the current size and growth of the Influenza Diagnostics market. It may include historical data, market segmentation by Type (e.g., RIDT, RT-PCR), and regional breakdowns.
麻豆原创 Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Influenza Diagnostics market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Influenza Diagnostics market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Influenza Diagnostics industry. This include advancements in Influenza Diagnostics technology, Influenza Diagnostics new entrants, Influenza Diagnostics new investment, and other innovations that are shaping the future of Influenza Diagnostics.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Influenza Diagnostics market. It includes factors influencing customer ' purchasing decisions, preferences for Influenza Diagnostics product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Influenza Diagnostics market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Influenza Diagnostics market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Influenza Diagnostics market.
麻豆原创 Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Influenza Diagnostics industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Influenza Diagnostics market.
麻豆原创 Segmentation:
Influenza Diagnostics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
RIDT
RT-PCR
Cell Culture
Others
Segmentation by application
Hospitals
POCT
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
BD
Abbott (Include Alere)
Roche
SIEMENS
Analytik Jena
Quidel
Thermo Fisher
Meridian Bioscience
BioMerieux
Sekisui Diagnostics
Response Biomedical
SA Scientific

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Influenza Diagnostics 麻豆原创 Size 2019-2030
2.1.2 Influenza Diagnostics 麻豆原创 Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Influenza Diagnostics Segment by Type
2.2.1 RIDT
2.2.2 RT-PCR
2.2.3 Cell Culture
2.2.4 Others
2.3 Influenza Diagnostics 麻豆原创 Size by Type
2.3.1 Influenza Diagnostics 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Influenza Diagnostics 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Influenza Diagnostics Segment by Application
2.4.1 Hospitals
2.4.2 POCT
2.4.3 Others
2.5 Influenza Diagnostics 麻豆原创 Size by Application
2.5.1 Influenza Diagnostics 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Influenza Diagnostics 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Influenza Diagnostics 麻豆原创 Size by Player
3.1 Influenza Diagnostics 麻豆原创 Size 麻豆原创 Share by Players
3.1.1 Global Influenza Diagnostics Revenue by Players (2019-2024)
3.1.2 Global Influenza Diagnostics Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Influenza Diagnostics Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Influenza Diagnostics by Regions
4.1 Influenza Diagnostics 麻豆原创 Size by Regions (2019-2024)
4.2 Americas Influenza Diagnostics 麻豆原创 Size Growth (2019-2024)
4.3 APAC Influenza Diagnostics 麻豆原创 Size Growth (2019-2024)
4.4 Europe Influenza Diagnostics 麻豆原创 Size Growth (2019-2024)
4.5 Middle East & Africa Influenza Diagnostics 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Influenza Diagnostics 麻豆原创 Size by Country (2019-2024)
5.2 Americas Influenza Diagnostics 麻豆原创 Size by Type (2019-2024)
5.3 Americas Influenza Diagnostics 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Influenza Diagnostics 麻豆原创 Size by Region (2019-2024)
6.2 APAC Influenza Diagnostics 麻豆原创 Size by Type (2019-2024)
6.3 APAC Influenza Diagnostics 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Influenza Diagnostics by Country (2019-2024)
7.2 Europe Influenza Diagnostics 麻豆原创 Size by Type (2019-2024)
7.3 Europe Influenza Diagnostics 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Influenza Diagnostics by Region (2019-2024)
8.2 Middle East & Africa Influenza Diagnostics 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Influenza Diagnostics 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Influenza Diagnostics 麻豆原创 Forecast
10.1 Global Influenza Diagnostics Forecast by Regions (2025-2030)
10.1.1 Global Influenza Diagnostics Forecast by Regions (2025-2030)
10.1.2 Americas Influenza Diagnostics Forecast
10.1.3 APAC Influenza Diagnostics Forecast
10.1.4 Europe Influenza Diagnostics Forecast
10.1.5 Middle East & Africa Influenza Diagnostics Forecast
10.2 Americas Influenza Diagnostics Forecast by Country (2025-2030)
10.2.1 United States Influenza Diagnostics 麻豆原创 Forecast
10.2.2 Canada Influenza Diagnostics 麻豆原创 Forecast
10.2.3 Mexico Influenza Diagnostics 麻豆原创 Forecast
10.2.4 Brazil Influenza Diagnostics 麻豆原创 Forecast
10.3 APAC Influenza Diagnostics Forecast by Region (2025-2030)
10.3.1 China Influenza Diagnostics 麻豆原创 Forecast
10.3.2 Japan Influenza Diagnostics 麻豆原创 Forecast
10.3.3 Korea Influenza Diagnostics 麻豆原创 Forecast
10.3.4 Southeast Asia Influenza Diagnostics 麻豆原创 Forecast
10.3.5 India Influenza Diagnostics 麻豆原创 Forecast
10.3.6 Australia Influenza Diagnostics 麻豆原创 Forecast
10.4 Europe Influenza Diagnostics Forecast by Country (2025-2030)
10.4.1 Germany Influenza Diagnostics 麻豆原创 Forecast
10.4.2 France Influenza Diagnostics 麻豆原创 Forecast
10.4.3 UK Influenza Diagnostics 麻豆原创 Forecast
10.4.4 Italy Influenza Diagnostics 麻豆原创 Forecast
10.4.5 Russia Influenza Diagnostics 麻豆原创 Forecast
10.5 Middle East & Africa Influenza Diagnostics Forecast by Region (2025-2030)
10.5.1 Egypt Influenza Diagnostics 麻豆原创 Forecast
10.5.2 South Africa Influenza Diagnostics 麻豆原创 Forecast
10.5.3 Israel Influenza Diagnostics 麻豆原创 Forecast
10.5.4 Turkey Influenza Diagnostics 麻豆原创 Forecast
10.5.5 GCC Countries Influenza Diagnostics 麻豆原创 Forecast
10.6 Global Influenza Diagnostics Forecast by Type (2025-2030)
10.7 Global Influenza Diagnostics Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 BD
11.1.1 BD Company Information
11.1.2 BD Influenza Diagnostics Product Offered
11.1.3 BD Influenza Diagnostics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 BD Main Business Overview
11.1.5 BD Latest Developments
11.2 Abbott (Include Alere)
11.2.1 Abbott (Include Alere) Company Information
11.2.2 Abbott (Include Alere) Influenza Diagnostics Product Offered
11.2.3 Abbott (Include Alere) Influenza Diagnostics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Abbott (Include Alere) Main Business Overview
11.2.5 Abbott (Include Alere) Latest Developments
11.3 Roche
11.3.1 Roche Company Information
11.3.2 Roche Influenza Diagnostics Product Offered
11.3.3 Roche Influenza Diagnostics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Roche Main Business Overview
11.3.5 Roche Latest Developments
11.4 SIEMENS
11.4.1 SIEMENS Company Information
11.4.2 SIEMENS Influenza Diagnostics Product Offered
11.4.3 SIEMENS Influenza Diagnostics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 SIEMENS Main Business Overview
11.4.5 SIEMENS Latest Developments
11.5 Analytik Jena
11.5.1 Analytik Jena Company Information
11.5.2 Analytik Jena Influenza Diagnostics Product Offered
11.5.3 Analytik Jena Influenza Diagnostics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Analytik Jena Main Business Overview
11.5.5 Analytik Jena Latest Developments
11.6 Quidel
11.6.1 Quidel Company Information
11.6.2 Quidel Influenza Diagnostics Product Offered
11.6.3 Quidel Influenza Diagnostics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Quidel Main Business Overview
11.6.5 Quidel Latest Developments
11.7 Thermo Fisher
11.7.1 Thermo Fisher Company Information
11.7.2 Thermo Fisher Influenza Diagnostics Product Offered
11.7.3 Thermo Fisher Influenza Diagnostics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 Thermo Fisher Main Business Overview
11.7.5 Thermo Fisher Latest Developments
11.8 Meridian Bioscience
11.8.1 Meridian Bioscience Company Information
11.8.2 Meridian Bioscience Influenza Diagnostics Product Offered
11.8.3 Meridian Bioscience Influenza Diagnostics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 Meridian Bioscience Main Business Overview
11.8.5 Meridian Bioscience Latest Developments
11.9 BioMerieux
11.9.1 BioMerieux Company Information
11.9.2 BioMerieux Influenza Diagnostics Product Offered
11.9.3 BioMerieux Influenza Diagnostics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 BioMerieux Main Business Overview
11.9.5 BioMerieux Latest Developments
11.10 Sekisui Diagnostics
11.10.1 Sekisui Diagnostics Company Information
11.10.2 Sekisui Diagnostics Influenza Diagnostics Product Offered
11.10.3 Sekisui Diagnostics Influenza Diagnostics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 Sekisui Diagnostics Main Business Overview
11.10.5 Sekisui Diagnostics Latest Developments
11.11 Response Biomedical
11.11.1 Response Biomedical Company Information
11.11.2 Response Biomedical Influenza Diagnostics Product Offered
11.11.3 Response Biomedical Influenza Diagnostics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.11.4 Response Biomedical Main Business Overview
11.11.5 Response Biomedical Latest Developments
11.12 SA Scientific
11.12.1 SA Scientific Company Information
11.12.2 SA Scientific Influenza Diagnostics Product Offered
11.12.3 SA Scientific Influenza Diagnostics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.12.4 SA Scientific Main Business Overview
11.12.5 SA Scientific Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.